ClinicalTrials.gg
Active, not recruitingNCT06653322Updated Aug 10, 2026

A Multi-centered,Randomized,Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma

A Phase 3 interventional study of HR-1703 and Placebo in Asthma With Eosinophilic Phenotype, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Active, not recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
401
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 6 under way, 2 of them phase 3. Asthma · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
2nd of 15
401 · median 84
Started
2024
with 1 other
Phase 3
2 of 15
1 open now
Registered
10th of 15
by date

Among the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., this one is the 2nd largest by enrollment, is one of 2 that started in 2024, is one of 2 in phase 3, and was the 10th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype

03

Conditions studied

  • Asthma With Eosinophilic Phenotype

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 12 years of age
  2. A minimum weight of 40kg
  3. A medical history of at least 1 year that meets the diagnosis of asthma;
  4. Current treatment with medium- or high- doses of ICS for at least 6 months and using steadily at least 3 months
  5. Current treatment with an additional controller medication, besides ICS, for at least 3 months and using steadily at least 1 month
  6. Absolute count of blood eosinophils suggests eosinophilic asthma
  7. During the screening period and baseline, pre- BD % \< 80%
  8. During the screening period and baseline, ACQ-6 score indicates asthma poor control
  9. History of severe asthma exacerbation within the past 12 months prior to screening
  10. Good compliance with eDiary completion
  11. Take efficient measures
  12. Voluntarily sign the form to participate in this study

Exclusion criteria

Exclusion Criteria:

  1. With other condition that could lead to elevated eosinophils
  2. With pulmonary diseases
  3. With existing immunodeficiency disease
  4. With other clinically significant diseases that may affect lung function
  5. With uncontrolled severe cardiovascular and cerebrovascular diseases
  6. With uncontrolled hypertension and/or diabetes
  7. With exacerbation, allergic rhinitis or sinusitis attacks, or clinical significant infection requiring intervention during 4 weeks prior to randomization
  8. Recent major surgeries or surgical plans during the study period, or treatment measures that investigators believe may affect subject evaluation
  9. Existing parasitic infections
  10. Diagnosed as malignant tumor within the first 5 years of randomization
  11. Significant abnormalities in screening period or baseline laboratory tests
  12. Screening period or baseline prolongation
  13. Prohibited drugs using during the pre randomization period
  14. Participated in other clinical trials within 30 days prior to screening and used research drugs containing active ingredients, or was still within 5 half lives of the research drug at the time of screening
  15. Smoking or quitting smoking for less than 6 months during screening, or previous smoking history ≥ 10 pack years
  16. History of drug use, alcoholism, or substance abuse within the past year prior to screening
  17. Allergic or intolerant to IL-5 monoclonal antibodies or other biological agents
  18. Pregnant or lactating subjects
  19. Other reasons why the researcher deemed it unsuitable for conducting this experiment
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
401 participants (actual)

Study arms

  • Experimental
    Subjects receiving SHR-1703 dose 1

    Drug: HR-1703

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugHR-1703

    HR-1703 will be administered by SC injection.

  • DrugPlacebo

    Matching Placebo will be administered by the SC injection.

06

What researchers measure

Primary outcomes

  1. Annualised asthma exacerbation rate,about 48weeks

    Time frame: about 48weeks

Secondary outcomes

  1. Mean number of days with oral corticosteroids taken for exacerbation,about 48weeks

    Time frame: about 48weeks

  2. Frequency of exacerbations requiring hospitalisation,about 48weeks

    Time frame: about 48weeks

  3. Time to first exacerbation requiring hospitalisation,about 48weeks

    Time frame: about 48weeks

  4. Mean change from baseline in clinic pre- and post-BD FEV1,about 64 weeks

    Time frame: about 64 weeks

  5. Mean change from baseline in clinic pre- and post-BD FEV1%,about 64weeks

    Time frame: about 64weeks

  6. Mean change from baseline in clinic pre- and post-BD FVC,about 64 weeks

    Time frame: about 64 weeks

  7. Mean change from baseline in clinic pre- and post-BD PEF,about 64 weeks

    Time frame: about 64 weeks

  8. Mean change from baseline in FeNO,about 64weeks

    Time frame: about 64weeks

  9. Mean change from baseline in asthma control questionnaire (ACQ-6) score,about 64 weeks

    Time frame: about 64 weeks

  10. Mean change from baseline in ASTHMA QUALITY OF LIFE QUESTIONNAIRES (AQLQ) score,about 64weeks

    Time frame: about 64weeks

  11. Mean change from baseline in Asthma symptom score at week 12/24/36/48/60,about 64weeks

    Time frame: at week 12/24/36/48/60,about 64weeks

  12. Mean change from baseline in daily rescue medication use at week 12/24/36/48/60,about 64weeks

    Time frame: at week 12/24/36/48/60,about 64weeks

  13. Mean change from baseline in awakening at night due to asthma symptoms requiring rescue medication use at week 12/24/36/48/60,about 64weeks

    Time frame: at week 12/24/36/48/60,about 64weeks

  14. Mean change from baseline in morning and evening PEF at week 12/24/36/48/60,about 64weeks

    Time frame: at week 12/24/36/48/60,about 64weeks

  15. Mean change from baseline in IgE,about 64weeks

    Time frame: about 64weeks

  16. Adverse events,about 64weeks

    Time frame: about 64weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Sep 2027, 34 months after the start.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 34 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2024
First posted
Oct 22, 2024
StartActual
Nov 21, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06653322
Responsible party
Sponsor
First posted
Oct 22, 2024
Start date
Nov 21, 2024
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 10, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion